175 related articles for article (PubMed ID: 12100188)
1. Fas and Fas ligand: expression and soluble circulating levels in cutaneous malignant melanoma.
Redondo P; Solano T; VAzquez B; Bauza A; Idoate M
Br J Dermatol; 2002 Jul; 147(1):80-6. PubMed ID: 12100188
[TBL] [Abstract][Full Text] [Related]
2. Expression of Fas ligand (CD95L) in primary malignant melanoma and melanoma metastases is associated with overall survival.
Neuber K; Eidam B
Onkologie; 2006 Sep; 29(8-9):361-5. PubMed ID: 16974112
[TBL] [Abstract][Full Text] [Related]
3. Fas-mediated apoptosis of melanoma cells and infiltrating lymphocytes in human malignant melanomas.
Shukuwa T; Katayama I; Koji T
Mod Pathol; 2002 Apr; 15(4):387-96. PubMed ID: 11950912
[TBL] [Abstract][Full Text] [Related]
4. Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in advanced melanoma.
Mouawad R; Khayat D; Soubrane C
Melanoma Res; 2000 Oct; 10(5):461-7. PubMed ID: 11095407
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of HBxAg in hepatocellular carcinoma and its relationship with Fas/FasL system.
Wang XZ; Chen XC; Chen YX; Zhang LJ; Li D; Chen FL; Chen ZX; Chen HY; Tao QM
World J Gastroenterol; 2003 Dec; 9(12):2671-5. PubMed ID: 14669310
[TBL] [Abstract][Full Text] [Related]
6. Frequent downregulation of Fas (CD95) expression and function in melanoma.
Bullani RR; Wehrli P; Viard-Leveugle I; Rimoldi D; Cerottini JC; Saurat JH; Tschopp J; French LE
Melanoma Res; 2002 Jun; 12(3):263-70. PubMed ID: 12140383
[TBL] [Abstract][Full Text] [Related]
7. Expression of Fas and Fas ligand in cutaneous B-cell lymphomas.
Zoi-Toli O; Meijer CJ; Oudejans JJ; de Vries E; van Beek P; Willemze R
J Pathol; 1999 Dec; 189(4):533-8. PubMed ID: 10629554
[TBL] [Abstract][Full Text] [Related]
8. Differential increase of Fas ligand expression on metastatic and thin or thick primary melanoma cells compared with interleukin-10.
Ekmekcioglu S; Okcu MF; Colome-Grimmer MI; Owen-Schaub L; Buzaid AC; Grimm EA
Melanoma Res; 1999 Jun; 9(3):261-72. PubMed ID: 10465582
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of soluble Fas ligand as a serological marker for melanoma.
Melzani G; Bugari G; Parrinello G; Mori G; Manganoni Au; De Panfilis G
Dermatology; 2002; 205(2):111-5. PubMed ID: 12218223
[TBL] [Abstract][Full Text] [Related]
10. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape.
Hahne M; Rimoldi D; Schröter M; Romero P; Schreier M; French LE; Schneider P; Bornand T; Fontana A; Lienard D; Cerottini J; Tschopp J
Science; 1996 Nov; 274(5291):1363-6. PubMed ID: 8910274
[TBL] [Abstract][Full Text] [Related]
11. Soluble Fas and soluble Fas ligand proteins in human milk: possible significance in the development of immunological tolerance.
Srivastava MD; Srivastava BI
Scand J Immunol; 1999 Jan; 49(1):51-4. PubMed ID: 10023857
[TBL] [Abstract][Full Text] [Related]
12. Prognostic relevance of altered Fas (CD95)-system in human breast cancer.
Mottolese M; Buglioni S; Bracalenti C; Cardarelli MA; Ciabocco L; Giannarelli D; Botti C; Natali PG; Concetti A; Venanzi FM
Int J Cancer; 2000 Mar; 89(2):127-32. PubMed ID: 10754489
[TBL] [Abstract][Full Text] [Related]
13. Prognostic relevance of Fas (APO-1/CD95) ligand in human colorectal cancer.
Sheehan KM; O'Donovan DG; Fitzmaurice G; O'Grady A; O'Donoghue DP; Sheahan K; Byrne MF; Conroy RM; Kay EW; Murray FE
Eur J Gastroenterol Hepatol; 2003 Apr; 15(4):375-80. PubMed ID: 12655257
[TBL] [Abstract][Full Text] [Related]
14. Expression of matrilysin (matrix metalloproteinase-7) in primary cutaneous and metastatic melanoma.
Kawasaki K; Kawakami T; Watabe H; Itoh F; Mizoguchi M; Soma Y
Br J Dermatol; 2007 Apr; 156(4):613-9. PubMed ID: 17493064
[TBL] [Abstract][Full Text] [Related]
15. Increased serum levels of soluble Fas in progressive B-CLL.
Osorio LM; Aguilar-Santelises M; De Santiago A; Hachiya T; Mellstedt H; Jondal M
Eur J Haematol; 2001 May; 66(5):342-6. PubMed ID: 11422415
[TBL] [Abstract][Full Text] [Related]
16. Increased Fas ligand expression in the tumor tissue and serum of patients with testicular germ cell tumors with seminomatous elements.
Hara S; Miyake H; Nakamura I; Arakawa S; Kamidono S; Hara I
Urology; 2001 Sep; 58(3):471-6. PubMed ID: 11549508
[TBL] [Abstract][Full Text] [Related]
17. Co-expression of Fas and Fas ligand in malignant glial tumors and cell lines.
Husain N; Chiocca EA; Rainov N; Louis DN; Zervas NT
Acta Neuropathol; 1998 Mar; 95(3):287-90. PubMed ID: 9542594
[TBL] [Abstract][Full Text] [Related]
18. Expression of CD95 ligand in melanocytic lesions as a diagnostic marker.
Maeda A; Aragane Y; Tezuka T
Br J Dermatol; 1998 Aug; 139(2):198-206. PubMed ID: 9767232
[TBL] [Abstract][Full Text] [Related]
19. Fas and Fas ligand: Expression and soluble circulating levels in bile duct carcinoma.
Murakami M; Sasaki T; Miyata H; Yamasaki S; Kuwahara K; Chayama K
Oncol Rep; 2004 Jun; 11(6):1183-6. PubMed ID: 15138553
[TBL] [Abstract][Full Text] [Related]
20. A comparative study of Fas and Fas-ligand expression during melanoma progression.
Soubrane C; Mouawad R; Antoine EC; Verola O; Gil-Delgado M; Khayat D
Br J Dermatol; 2000 Aug; 143(2):307-12. PubMed ID: 10951137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
